NLS Global report

In a sector long dominated by the US and Europe, Mainland China is now catching up in global pharma and biotechnology. 

Europe ranks highly when it comes to life science know-how and knowledge, but the region is falling behind when it comes to R&D and turning science into real-world solutions. Complex regulations, a fragmented market, scattered funding, and the potential US market tariffs are just some of the challenges ahead.

The exclusive global, ex-China, licensing agreement concerns the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.

While reports of federal cutbacks across the US health, life sciences, and research landscapes continue to fuel anxiety among scientists, the situation may not be as dire as people fear, according to one investor.

On May 12, US President Trump signed an Executive Order to bring the prices Americans and taxpayers pay for prescription drugs in line with those paid by similar nations.

The policy prevents the NSF from awarding new research grants and from supplying allotted funds for existing grants, such as those that receive yearly increments of money.